Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Clearmind Medicine Inc. (Nasdaq: CMND) announced promising results from a study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The research, led by Prof. Joseph Tam at the Hebrew University of Jerusalem, revealed significant findings:
1. Weight loss: MEAI reduced diet-induced obesity in mice, decreasing fat mass while preserving lean mass.
2. Improved metabolism: MEAI enhanced glycemic control by reducing hyperglycemia, glucose intolerance, and hyperinsulinemia.
3. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels.
4. Increased energy expenditure: MEAI boosted energy expenditure and fat utilization without affecting food consumption.
5. Activity: MEAI increased activity-specific energy expenditure without overstimulation.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, highlighted MEAI's potential as a breakthrough in obesity treatment, citing its efficacy, unique mechanism of action, and easy administration without food consumption constraints.
Clearmind Medicine Inc. (Nasdaq: CMND) ha annunciato risultati promettenti da uno studio su 5-metossido-2-aminoindano (MEAI) per combattere l'obesità. La ricerca, guidata dal Prof. Joseph Tam presso l'Università Ebraica di Gerusalemme, ha rivelato risultati significativi:
1. Perdite di peso: il MEAI ha ridotto l'obesità indotta dalla dieta nei topi, diminuendo la massa grassa mentre preservava la massa magra.
2. Metabolismo migliorato: il MEAI ha migliorato il controllo glicemico riducendo l'iperglicemia, l'intolleranza al glucosio e l'iperinsulinemia.
3. Malattia del fegato grasso: il MEAI ha ridotto il fegato grasso abbassando i livelli di trigliceridi e colesterolo nel fegato.
4. Aumento della spesa energetica: il MEAI ha aumentato il dispendio energetico e l'utilizzo dei grassi senza influenzare il consumo di cibo.
5. Attività: il MEAI ha aumentato la spesa energetica specifica per l'attività senza provocare sovrastimolazione.
Il Dr. Adi Zuloff-Shani, CEO di Clearmind Medicine, ha evidenziato il potenziale del MEAI come una svolta nel trattamento dell'obesità, citando la sua efficacia, il meccanismo d'azione unico e la facilità di somministrazione senza vincoli di consumo alimentare.
Clearmind Medicine Inc. (Nasdaq: CMND) anunció resultados prometedores de un estudio sobre 5-metoxi-2-aminoindano (MEAI) para combatir la obesidad. La investigación, liderada por el Prof. Joseph Tam en la Universidad Hebrea de Jerusalén, reveló hallazgos significativos:
1. Pérdida de peso: el MEAI redujo la obesidad inducida por la dieta en ratones, disminuyendo la masa grasa mientras preservaba la masa magra.
2. Mejora del metabolismo: el MEAI mejoró el control glucémico al reducir la hiperglucemia, la intolerancia a la glucosa y la hiperinsulinemia.
3. Enfermedad del hígado graso: el MEAI disminuyó el hígado graso al reducir los niveles de triglicéridos y colesterol en el hígado.
4. Aumento del gasto energético: el MEAI incrementó el gasto energético y la utilización de grasas sin afectar el consumo de alimentos.
5. Actividad: el MEAI aumentó el gasto energético específico para la actividad sin sobreactivación.
El Dr. Adi Zuloff-Shani, CEO de Clearmind Medicine, destacó el potencial del MEAI como un avance en el tratamiento de la obesidad, citando su eficacia, su mecanismo de acción singular y su fácil administración sin restricciones de consumo de alimentos.
Clearmind Medicine Inc. (Nasdaq: CMND)는 비만 치료를 위한 5-메톡시-2-아미노인단(MEAI)에 대한 연구에서 유망한 결과를 발표했습니다. 이 연구는 예루살렘 히브리 대학의 조셉 탐 교수에 의해 주도되었으며, 중요한 발견을 드러냈습니다:
1. 체중 감소: MEAI는 쥐에서 식이 요인으로 인한 비만을 줄이며 지방량을 감소시키고 근육량을 유지했습니다.
2. 신진대사 개선: MEAI는 고혈당, 포도당 불내성 및 고인슐린증을 줄여 혈당 조절을 개선했습니다.
3. 지방간 질환: MEAI는 간의 트리글리세리드와 콜레스테롤 수치를 낮추어 지방간을 감소시켰습니다.
4. 에너지 소비 증가: MEAI는 음식 섭취에 영향을 미치지 않으면서 에너지 소비와 지방 활용을 증가시켰습니다.
5. 활동: MEAI는 과도 자극 없이 활동 특정 에너지 소비를 증가시켰습니다.
클리어마인드 메디슨의 CEO인 아디 줄로프-샤니 박사는 MEAI의 비만 치료에서의 잠재력을 강조하며, 그 효능, 독특한 작용 메커니즘 및 음식을 섭취하지 않고도 쉽게 투여할 수 있는 점을 언급했습니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a annoncé des résultats prometteurs d'une étude sur 5-méthoxy-2-aminoindane (MEAI) pour lutter contre l'obésité. La recherche, dirigée par le Prof. Joseph Tam à l'Université hébraïque de Jérusalem, a révélé des découvertes significatives :
1. Perte de poids: le MEAI a réduit l'obésité induite par l'alimentation chez les souris, en diminuant la masse grasse tout en préservant la masse maigre.
2. Métabolisme amélioré: le MEAI a amélioré le contrôle glycémique en réduisant l'hyperglycémie, l'intolérance au glucose et l'hyperinsulinémie.
3. Maladie du foie gras: le MEAI a diminué la maladie du foie gras en abaissant les niveaux de triglycérides et de cholestérol dans le foie.
4. Dépense énergétique accrue: le MEAI a augmenté la dépense énergétique et l'utilisation des graisses sans affecter la consommation alimentaire.
5. Activité: le MEAI a augmenté la dépense énergétique spécifique à l'activité sans surstimulation.
Le Dr. Adi Zuloff-Shani, PDG de Clearmind Medicine, a souligné le potentiel du MEAI en tant que percée dans le traitement de l'obésité, en citant son efficacité, son mécanisme d'action unique et sa facilité d'administration sans contraintes de consommation alimentaire.
Clearmind Medicine Inc. (Nasdaq: CMND) gab vielversprechende Ergebnisse aus einer Studie zu 5-Methoxy-2-Aminoindan (MEAI) zur Bekämpfung von Fettleibigkeit bekannt. Die Forschung, die von Prof. Joseph Tam an der Hebräischen Universität Jerusalem geleitet wurde, offenbarte bedeutende Erkenntnisse:
1. Gewichtsverlust: MEAI reduzierte die durch Ernährung induzierte Fettleibigkeit bei Mäusen, verringerte die Fettmasse und erhielt die fettfreie Masse.
2. Verbesserter Stoffwechsel: MEAI verbesserte die glykämische Kontrolle, indem es Hyperglykämie, Glukosetoleranz und Hyperinsulinämie verringerte.
3. Fettlebererkrankung: MEAI verringerte die Fettleber, indem es die Lebertriglycerid- und Cholesterinspiegel senkte.
4. Erhöhte Energieausgabe: MEAI steigerte die Energieausgabe und die Fettverwertung, ohne die Nahrungsaufnahme zu beeinflussen.
5. Aktivität: MEAI erhöhte die aktivitätsspezifische Energieabgabe ohne Überstimulation.
Dr. Adi Zuloff-Shani, CEO von Clearmind Medicine, hob das Potenzial von MEAI als Durchbruch bei der Behandlung von Fettleibigkeit hervor und betonte dessen Wirksamkeit, einzigartigen Wirkmechanismus und einfache Anwendung ohne Essensrestriktionen.
- MEAI demonstrated significant weight loss effects in mice studies
- MEAI improved glycemic control and metabolic function
- MEAI reduced fatty liver disease markers
- MEAI increased energy expenditure without affecting food intake
- Study results position MEAI as a potential breakthrough in obesity treatment
- None.
Insights
The publication of this study in ACS Pharmacology and Translational Science marks a significant milestone for Clearmind Medicine's MEAI compound. The research demonstrates promising results for weight loss and metabolic improvements in a mouse model, which could potentially translate to human applications.
Key findings include:
- Reduced diet-induced obesity while preserving lean mass
- Improved glycemic control
- Decreased fatty liver disease markers
- Increased energy expenditure without overstimulation
This scientific publication could significantly impact Clearmind Medicine's market position. The global obesity treatment market was valued at
Investors should note that while these results are promising, the drug development process is long and costly. Clearmind will need substantial capital to fund human trials and potential commercialization. The company's ability to secure funding and partnerships will be important for its future success. Additionally, competition in the obesity drug market is fierce, with established players and other novel treatments in development.
MEAI's potential as a weight loss drug is intriguing, especially given its multifaceted approach to obesity treatment. Unlike some current treatments that focus solely on appetite suppression, MEAI appears to address multiple aspects of metabolism. This could potentially lead to more effective and sustainable weight loss outcomes.
However, the path to market is challenging. The FDA has stringent requirements for weight loss drugs, including demonstrating long-term safety and efficacy. Recent high-profile withdrawals of obesity drugs due to safety concerns have made the regulatory environment even more cautious. Clearmind will need to conduct extensive clinical trials to prove MEAI's safety profile, especially given its psychedelic-derived nature. The company's ability to navigate these regulatory challenges will be important for MEAI's commercial success.
Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem.
Key findings from the study include:
- Weight loss: MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass.
- Improved Metabolism: MEAI significantly improved glycemic control by reducing hyperglycemia, glucose intolerance and hyperinsulinemia, highlighting its therapeutic potential in regulating glucose metabolism.
- Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation.
- Increased Energy Expenditure: MEAI increased energy expenditure and fat utilization while maintaining a similar food consumption.
- Activity: MEAI increased activity-specific energy expenditure without overstimulation supporting its potential to impact energy balance.
These findings are based on the results from Clearmind Medicine’s study aimed to investigate the ability of MEAI to modulate metabolism and counteract obesity. This comprehensive study was published in ACS Pharmacology and Translational Science, https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00353.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented, "The newly published paper shows the efficacy of MEAI as a promising therapeutic approach for weight loss and normalization of metabolic disorders. The comprehensive experiments demonstrate the ability of MEAI to significantly reduce weight by lowering the fat mass, improve the body's metabolic function and lower fat accumulation in the liver, all of which position this treatment as a potential breakthrough in the treatment of obesity. We are excited by the potential of MEAI, which may position it at the forefront of weight loss treatments, even compared to the marketed treatments in the percentage of weight loss, its unique mechanism of action, the easy administration and in the fact that no food consumption constrains are required."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 28 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the efficacy of MEAI as a promising therapeutic approach for weight loss and normalization of metabolic disorders, MEAI’s position potential breakthrough in the treatment of obesity and the potential of MEAI, which may position it at the forefront of weight loss treatments. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What are the key findings of Clearmind Medicine's MEAI study for obesity treatment?
How does MEAI (CMND) compare to current weight loss treatments?
Where was the Clearmind Medicine (CMND) MEAI study published?
Who led the research on MEAI for Clearmind Medicine (CMND)?
